ANALYSIS: US FDA boost narrows gap for ReShape in obesity balloon race
This article was originally published in Clinica
Executive Summary
ReShape Medical has received a boost after the US FDA reportedly said it would not need to go through an advisory panel meeting for its ReShape Duo obesity balloon. ReShape submitted a premarket approval application to the agency in July 2014; it is designed to help weight loss in patients with a body mass index of 30-40.